Lead PanBITAP prostate program
Development stages
Preclinical development · Cancer immunotherapy
Stopping cancer
before it returns.
PanBITAP for high-risk prostate cancer.
We combine computational peptide design with functional immune testing to develop an off-the-shelf vaccine for use after primary therapy.
Computational design Functional evidenceOur approach
Development focus
PanBITAP.
Built on BITAP.
Our lead program is PanBITAP, a fixed-composition peptide vaccine in preclinical development for high-risk prostate cancer after primary therapy.
PanBITAP builds on the individualized BITAP platform and its published treatment experience. We combine computational peptide design with functional immune testing to select candidates and develop an off-the-shelf formulation for eligible patients.
Our scientific approachCurrent position
Evidence and development.
Published BITAP case reports
Individual treatment evidenceR&D co-funded by the EU and Brandenburg
Research fundingBioinformatics meets peptide design
Many signals.
One clear direction.
Connecting biological data, epitope prediction
and peptide engineering.
01 Rank candidates02 Measure immune responses03 Refine the design
Our pipeline
Individualized experience.
Off-the-shelf development.
Current development stageIndividual treatment experience
| Program | Indication | Target evaluation | Preclinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|
BITAPIndividualized peptide immunotherapy | Prostate, pancreatic and breast cancer | Individual treatment experience3 published case reports Published case reports | ||||
PanBITAPFixed-composition peptide vaccine | High-risk prostate cancer after primary therapy | Preclinical validation Phase I proposed; subject to protocol and regulatory review. | ||||
PanBITAPFixed-composition peptide vaccine | Undisclosed indication 01 | Bioinformatic target evaluation | ||||
PanBITAPFixed-composition peptide vaccine | Undisclosed indication 02 | Bioinformatic target evaluation | ||||
BITAP
Individualized peptide immunotherapy
Prostate, pancreatic and breast cancer
Individual treatment experience3 published case reports
Published case reportsPanBITAP
Fixed-composition peptide vaccine
High-risk prostate cancer after primary therapy
Preclinical validation
Phase I proposed; subject to protocol and regulatory review.
PanBITAP
Fixed-composition peptide vaccine
Undisclosed indication 01
Bioinformatic target evaluation
PanBITAP
Fixed-composition peptide vaccine
Undisclosed indication 02
Bioinformatic target evaluation
Individual treatment attempts are distinct from clinical trials. PanBITAP is in preclinical development; Phase I is proposed and has not started.
Our team
The people behind
the science.
Scientists and medical professionals working across disciplines to advance immunotherapy.
Florian Buhr, PhD
Dr. phil. nat.
CEO & Chief Scientific Officer
Read biography
Nils H. Thoennissen, MD PhD
PD Dr. med.
Chief Medical Officer
Read biography
Elmar Burchardt, MD PhD
PD Dr. med. Dr. rer. biol. hum.
Chief Strategy Officer
Read biographyFounded by those directly impacted. Driven by a shared purpose.
Meet the full teamNewsroom